Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York City, NY, discusses the use of circulating tumor DNA (ctDNA) as a biomarker in the prognostication of patients with multiple myeloma. Prof. Morgan explains that peripheral blood collection for tumor DNA biomarker testing may carry less burden for patients than the traditional bone marrow testing. However, Prof. Morgan notes that these circulating biomarkers are currently less reliable, less sensitive, and more difficult to use in the context of myeloma, and that this technique will require optimization before it becomes the standard of care in clinical practice. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть